A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients

Inclusion criteria

• Histologically diagnosed high-grade serous or endometrioid ovarian cancer (including primary peritoneal and fallopian tube cancer)
• Completion of ≥2 previous platinum-containing regimens
• Complete response (CR) or partial response (PR) achieved with last platinum-based chemotherapy regimen as determined by investigator
• Ability to be randomized ≤8 weeks after last dose of platinum

Exclusion criteria

• Prior treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor
• Patients who have received other study drug treatment within 4 weeks prior to the first administration(< 5 elimination half-lives of the study drug molecular targeted anti-cancer drugs).
• Patients with clinical symptoms of cancer ascites, pleural effusion, who need to drainage, or who have undergone ascites drainage within 2 months prior to the first administration.